Boston Scientific Corp (BSX-N) Stock Predictions - Stockchase
WATCH LIST
23
Boston Scientific Corp (BSX-N)

ON STOCKCHASE SINCE May 2003

biotechnology/pharmaceutical

Boston Scientific Corp

BSX-N

7 watching          
Join the Discussion

Boston Scientific Corp (BSX-N) SAVE Apr, 19, 2019, 7:40 am

35.11 0.2 (0.57%)

About Boston Scientific Corp (BSX-N)

Boston Scientific Corporation is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a range of interventional medical specialties, including interventional ... More at Wikipedia

What the experts are saying about BSX-N



  • All
  • Filtered
Signal Opinion Expert
BUY
BSX-N vs. TFX-N. TFX-N is a smaller high growth company. BSX-N is a market leader but recovering from a few years of bad management. He has a low $40s target in a year. He would stick with it.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
BSX-N vs. TFX-N. TFX-N is a smaller high growth company. BSX-N is a market leader but recovering from a few years of bad management. He has a low $40s target in a year. He would stick with it.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Bruce Murray

CEO & Chie, The Murray Wealth Gr...

Price Price
$37.825
Owned Owned
Yes

BUY
He still loves this name. You can still buy it in the low $30s and he has a target of the low $40s. They are making acquisitions.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
He still loves this name. You can still buy it in the low $30s and he has a target of the low $40s. They are making acquisitions.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Bruce Murray

CEO & Chie, The Murray Wealth Gr...

Price Price
$34.420
Owned Owned
Yes

BUY
Boston Scientific Corp(BSX-N) 

September 18, 2018

He sold shares in Medtronics (MDT-N) to buy this, which he sees as more of a turnaround play. He sees higher growth prospects in their more targeted business model.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

He sold shares in Medtronics (MDT-N) to buy this, which he sees as more of a turnaround play. He sees higher growth prospects in their more targeted business model.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Bruce Murray

CEO & Chie, The Murray Wealth Gr...

Price Price
$37.620
Owned Owned
Yes

TOP PICK
Boston Scientific Corp(BSX-N) 

September 18, 2018

The company has raised its growth rate from 5-to-7% to 7-to-10% range. This is a strong turnaround, and he is excited about medical stocks doing better. Yield 0%. (Analysts’ price target is $38.78)

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

The company has raised its growth rate from 5-to-7% to 7-to-10% range. This is a strong turnaround, and he is excited about medical stocks doing better. Yield 0%. (Analysts’ price target is $38.78)

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Bruce Murray

CEO & Chie, The Murray Wealth Gr...

Price Price
$37.620
Owned Owned
Yes

BUY

He likes it. They are in cardiac arrhythmia management and cardiology devices. Best in class organic growth. They made 8 acquisitions over the past year or so. Might be a target for an acquisition. One of his favorites option candidates. 

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

He likes it. They are in cardiac arrhythmia management and cardiology devices. Best in class organic growth. They made 8 acquisitions over the past year or so. Might be a target for an acquisition. One of his favorites option candidates. 

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Paul Macdonald

Chief Inve, Harvest Portfolios G...

Price Price
$33.220
Owned Owned
Yes

BUY

On the 5 year chart you can see it is in an uptrend.  It is quite tradable.  It began to find a lid just under $30.  Buy in the low $20s and sell in the high $20’s.  Don’t own it for the long run.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

On the 5 year chart you can see it is in an uptrend.  It is quite tradable.  It began to find a lid just under $30.  Buy in the low $20s and sell in the high $20’s.  Don’t own it for the long run.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Keith Richards

Portfolio , ValueTrend Wealth Ma...

Price Price
$26.840
Owned Owned
Unknown

HOLD

No dividend, focussed on cardiac equipment like pacemakers. Have made many acqusitions in past years. Fabulous management. Have driven cost synergies consistently. Beat estimates recently. Forward earnings are 20x. A solid hold.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

No dividend, focussed on cardiac equipment like pacemakers. Have made many acqusitions in past years. Fabulous management. Have driven cost synergies consistently. Beat estimates recently. Forward earnings are 20x. A solid hold.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Paul Macdonald

Chief Inve, Harvest Portfolios G...

Price Price
$27.660
Owned Owned
Yes

COMMENT

If you own healthcare providers, especially in the hospital supply area, they have been great stocks for a long time. We are all getting older and need more help. Prefers Medtronic (MDT-N) a little better. However, this is another dividend growth story, so you can’t go wrong here.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

If you own healthcare providers, especially in the hospital supply area, they have been great stocks for a long time. We are all getting older and need more help. Prefers Medtronic (MDT-N) a little better. However, this is another dividend growth story, so you can’t go wrong here.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
John Burke

CEO & CIO, Burke Financial Stra...

Price Price
$28.820
Owned Owned
No

HOLD

An extraordinarily well-run company. Great organic growth. A leader in the cardiac rhythm management, and have done that principally organically. The new management in 2012 streamlined operations, became very efficient and enhanced margins on the back of that. This is a company that he wants to continue to own.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

An extraordinarily well-run company. Great organic growth. A leader in the cardiac rhythm management, and have done that principally organically. The new management in 2012 streamlined operations, became very efficient and enhanced margins on the back of that. This is a company that he wants to continue to own.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Paul Macdonald

Chief Inve, Harvest Portfolios G...

Price Price
$22.660
Owned Owned
Yes

BUY

Thinks this is a good time to be investing in manufacturers of medical devices. There is a whole seasonality that starts in January with a little bit of a pickup in February. They tend to peak every year right around August/September, so there is a bit of time to ride this out.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

Thinks this is a good time to be investing in manufacturers of medical devices. There is a whole seasonality that starts in January with a little bit of a pickup in February. They tend to peak every year right around August/September, so there is a bit of time to ride this out.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Hap (Robert) Sn

Chief Port, Castlemoore Inc....

Price Price
$19.470
Owned Owned
Unknown

DON'T BUY
Boston Scientific Corp(BSX-N) 

September 14, 2010

In the last 9 months they had their heart defibrillator withdrawn from the US market because of FDA problems. Would steer clear of this one.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
In the last 9 months they had their heart defibrillator withdrawn from the US market because of FDA problems. Would steer clear of this one.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Gordon Reid

President, GoodReid Investment ...

Price Price
$5.330
Owned Owned
No

DON'T BUY
Had an earnings disappointment. FMV trend is sharply down. When factoring in analysts forecasts, the FMV is about $12.30.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Had an earnings disappointment. FMV trend is sharply down. When factoring in analysts forecasts, the FMV is about $12.30.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Ross Healy

Chairman, Strategic Analysis C...

Price Price
$15.950
Owned Owned
No

BUY on WEAKNESS
Boston Scientific Corp(BSX-N) 

September 21, 2005

Will have to go to $20.50 before it has a bounce. Has a model price of $31.95 which is a 37/38% differential.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Will have to go to $20.50 before it has a bounce. Has a model price of $31.95 which is a 37/38% differential.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Brian Acker, CA

Chief Exec, Acker Finley Inc....

Price Price
$23.170
Owned Owned
Unknown

BUY
Boston Scientific Corp(BSX-N) 

September 6, 2005

In a lawsuit with Johnson and Johnson (JNJ-N), so a lot depends on who wins the case. Their product works better than JNJ and he continues to like it.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
In a lawsuit with Johnson and Johnson (JNJ-N), so a lot depends on who wins the case. Their product works better than JNJ and he continues to like it.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Gavin Graham

Trustee, Pointbreak ETFs...

Price Price
$26.210
Owned Owned
Yes

BUY
Things look good for them. Won a patent case against Johnson & Johnson (JNJ-N).
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Things look good for them. Won a patent case against Johnson & Johnson (JNJ-N).
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Gavin Graham

Trustee, Pointbreak ETFs...

Price Price
$27.480
Owned Owned
Yes

Showing 1 to 15 of 23 entries
Successfully Saved Company
Successfully Saved Company
4+
JOIN THE DISCUSSION
4 comments in the last 7 days